Key result
YM337 reduced the ratio of infarcted area to the whole cerebrum compared to saline in monkeys with focal cerebral ischemia.
Why the study?
Does YM337 reduce infarct area and neurologic deficits in monkeys with thrombotic distal middle cerebral artery occlusions?
Does YM337 reduce infarct area and neurologic deficits in monkeys with thrombotic distal middle cerebral artery occlusions?
Blockade of glycoprotein IIb/IIIa with YM337 lessens infarct size and neurologic deficits in a primate model of cerebral artery thrombosis.
Answers are grounded in this paper and cite their sources.
Supports glycoprotein IIb/IIIa blockade in primate cerebral ischemia models; leaves open translation to human stroke therapy.
To elucidate the role of platelets in brain damage during focal cerebral ischemia, the effect of YM337, a glycoprotein IIb/IIIa antagonist, on infarct areas and neurologic deficits was measured in monkeys with thrombotic distal middle cerebral artery occlusions. Distal middle cerebral arteries were occluded by a platelet-rich thrombus formed after photochemical reaction between rose bengal dye and green light. The experimental drugs were intravenously injected 30 min after rose bengal injection and continuously infused for 24 h thereafter. YM337, but not the thromboxane A2 synthetase inhibitor sodium ozagrel, significantly inhibited ex vivo ADP-induced platelet aggregation. The percentage of ADP-induced platelet aggregation 4 h after the start of administration was 87.0% of predosing value in the saline group, 55.6% in the YM337 low dose group, 28.8% in the YM337 high dose group and 89.0% in the sodium ozagrel group. However, while sodium ozagrel significantly inhibited thromboxane B2 generation accompanying arachidonic acid-induced platelet aggregation, YM337 had little effect on this pathway. The neurologic deficit was milder and infarct area significantly smaller in the YM337-treated groups compared with the saline control group. The ratio of infarcted area to the whole area of the cerebrum was 12.3% in the saline group, 5.5% in the YM337 low dose group, 5.7% in the YM337 high dose group, and 11.0% in the ozagrel group. These results suggest that a blockade of glycoprotein IIb/IIIa is a beneficial approach to treat cerebral artery thrombosis and cerebral infarction. Drug Dev. Res. 45:162–169, 1999.
No takes yet. Share an insight, caveat, or question.
Kaku et al. (1999) studied focal cerebral ischemia. YM337 vs. saline and sodium ozagrel was evaluated on ratio of infarcted area to the whole area of the cerebrum. YM337 reduced the ratio of infarcted area to the whole cerebrum compared to saline in monkeys with focal cerebral ischemia.
Synapse has enriched 10 related papers. Consider them for comparative context: